We offer our registered users tailored information, free online courses and exclusive content.
Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?
... or you lost your password?
In spite of increased knowledge and the ongoing efforts of scientific societies, cardiovascular diseases remain the first cause of mortality and morbidity in the Asia-Pacific regions as well as in the rest of the world. Treatment of major cardiovascular diseases including acute coronary syndrome or stroke present a significant and costly challenge for the health systems - without taking into consideration that the most effective therapy for these diseases is prevention based on effective control of risk factors.
Essential hypertension remains an unsolved problem in cardiovascular medicine, not least because it is often complicated by metabolic disease. Most hypertensive patients are still not receiving the correct pharmacological treatment and may not have their blood pressure values suitably normalised. There is a clear need to promote clinical management of hypertension that is derived from evidence-based medicine and scientific guidelines, and to ensure that scientific knowledge is transformed into clinical practice.
Serono Symposia International Foundation is proud to organise the 2014 Asia-Pacific Cardiology Symposium “Managing cardiovascular risk factors to prevent the fatal end of cardiovascular continuum”.
This live educational symposium will examine recent evidence in the treatment of hypertension with a specific focus on the correct utilisation of the 'old` drugs such as beta-blockers and the 'new` therapeutic approaches such as renal denervation. Sessions will also be devoted to discussing emerging health problems in the Asia-Pacific area and will offer possible solutions to the management of patients with
hypertension complicated by other risk factors or related diseases.
By attending this live educational symposium participants will be able to:
An application has been submitted to the EBAC for CME accreditation of the Serono Symposia International Foundation symposium 2014 Asia-Pacific cardiovascular symposium "Managing cardiovascular risk factors to prevent the fatal end of cardiovascular continuum" to be held on 1-2 March 2014 -Guangzhou, China.
Serono Symposia International Foundation (SSIF) adheres to the principles of the Good CME Practice Group (gCMEp)
Saturday, 1 March
Final programme and abstracts
09.00 Introductory lecture
Lin Shuguang (China)
09.15 L1: Novelties from recent guidelines in hypertension (video lecture)
Marlon T. Co (Philippines)
Session I Specific issues in the pharmacological treatment of hypertension
Chairman: Lin Shuguang (China)
09.35 L2: Does a first-choice treatment exist?
Stefano Taddei (Italy)
09.55 D1: Debate on beta blockers:
- PROS Soetanto Arieska Soenarta (Indonesia)
Cons- Jamshed J. Dalal (India)
10.25 CC1: Clinical case
Soetanto Arieska Soenarta (Indonesia)
Session II Specific problems in APAC
Chairman: Jamshed J. Dalal (India)
11.30 L3: Metabolic Burden
Piyamitr Sritara (Thailand)
11.50 L4: Differences in drug responsiveness to hypertensive drugs
Brian Tomlinson (China) Video lecture
12.15 L5: Pollution factors
Stefano Taddei (Italy) Pollution factors
Session III Hypertension in special population
Chairman: Roberto Ferrari (Italy)
CC2: Clinical cases
14.00 Diabetic population
Hung-Fat Tse (China)
14.30Young and middle age obese population
Bambang Budi Siswanto (Indonesia)
Session IV Beta blockers for management of cardiovascular diseases: are all beta- blockers the same?
Chairman: Hung-Fat Tse (China)
15.30 L6: Beta-blockers in Asian patients: pharmacodynamics, pharmacokinetics, pharmacogenetics ( video lecture)
Brian Tomlinson (China)
15.50 L7: Comparing two beta-blockers in patients with hypertension
Aniruddha Dharmadhikari (India)
16.10 L8: Comparison of two beta-blockers on sympathetic nervous activity and central aortic pressure in hypertensive patients
Gao Pinjin (China)
Sunday, 2 March
Session V New therapeutic approach in hypertension: the role of heart rate
Chairman: Stefano Taddei (Italy)
09.00 L9: Sympathetic nervous system and hypertension: an overview
Guido Grassi (Italy)
09.20 D2: Debate: is heart rate a target in hypertensive treatment?
Pro Guido Grassi (Italy)
Cons Phrommintikul Arintaya (Thailand)
Session VI Hypertension and related diseases
Chairman: Brian Tomlinson (China)
10.45 L10: Hypertension and atrial fibrillation
Claudio Borghi (Italy)
11.15 L11: Coronary artery disease
Roberto Ferrari (Italy)
11.45 L12: Heart failure
Roberto Ferrari (Italy)
Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of Serono Symposia International Foundation. All presentations represent solely the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:
Claudio Borghi Declared receipts of grants and contract from Manarini international. Declared receipt of honoraria or consultation fees from Manarini, St. Jude medical, Servier, Berlin Chemie. Declared to be member of a company advisory board, board of directors or other similar group of: Ely-Lilly, Menarini. Declared participation in a company sponsored speakers’ bureau of: Menarini, Servier, St. Jude medical.
Jamshed J. Dalal Declared no potential conflict of interest.
Aniruddha Dharmadhikari Declared no potential conflict of interest.
Roberto Ferrari Declared receipt of research grant from: Boehringer Ingelheim, Novartis, Servier, Irbtech. Declared receipt of honoraria or consultation fees from: Boehringer Ingelheim, Servier. Declared participation in a company sponsored speakers’ bureau of: Boehringer Ingelheim , Servier and Merck Serono.
Guido Grassi Declared receipt of honoraria or consultation fees from: Medtronic, Boston, Scientific, Malesci. Declared participation in a company sponsored speakers’ bureau of: Medtronic.
Gao Pinjin Declared no potential conflict of interest.
Soetanto Arieska Soenarta Declared no potential conflict of interest.
Piyamitr Sritara Declared no potential conflict of interest.
Stefano Taddei Declared receipt of grants and contracts from Novartis, Servier, Boehringer. Declared participation in a company sponsored speakers’ bureau of Servier, Stroder, Pfizer, Bayer, Msd and Boehringer.
Brian Tomlinson Declared receipts of research funding from Amgen, AstraZeneca, Bristol-Mayers Squibb, Genzyme, GlaxoSmith Kline, Merck Serono and Dohme, Novartis, Roche and Tajeda. Declared receipt of honoraria or consultation fees from: Amgen, Janssen and Merck Serono. Declared to be member of a company advisory board, board of directors or other similar group of: Amgen, Janssen and Merck Serono. Declared participation in a company sponsored speakers’ bureau of: Merck Serono, Merck Sharp and Dohme, Ranbaxy, Servier.
Hung-Fat Tse Declared no potential conflict of interest.
The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 18 February 2014.
Bambang Budi Siswanto
Marlon T. Co
Phrommintikul Arintaya
Lin Shuguang
